Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708

Article  PubMed  Google Scholar 

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1

Article  CAS  PubMed  Google Scholar 

Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM et al (2021) Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational multicenter retrospective study. Liver Cancer 10(2):107–114. https://doi.org/10.1159/000512781

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. https://doi.org/10.1056/NEJMoa0708857

Article  CAS  PubMed  Google Scholar 

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57(4):821–829. https://doi.org/10.1016/j.jhep.2012.06.014

Article  CAS  PubMed  Google Scholar 

Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP et al (2016) Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 65(6):1140–1147. https://doi.org/10.1016/j.jhep.2016.07.020

Article  CAS  PubMed  Google Scholar 

Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G et al (2022) Real life study of lenvatinib therapy for hepatocellular carcinoma: RELEVANT study. Liver Cancer 11(6):527–539. https://doi.org/10.1159/000525145

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E et al (2021) Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy. Cancer Manag Res 13:9379–9389. https://doi.org/10.2147/CMAR.S330195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J, Sung PS, Yang H, Lee SK, Nam HC, Yoo SH et al (2020) A real-world comparative analysis of lenvatinib and sorafenib as a salvage therapy for transarterial treatments in unresectable HCC. J Clin Med 9(12):4121. https://doi.org/10.3390/jcm9124121

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745

Article  CAS  PubMed  Google Scholar 

Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP et al (2020) Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol 38(36):4317–4345. https://doi.org/10.1200/JCO.20.02672

Article  CAS  PubMed  Google Scholar 

Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR et al (2021) Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 73(Suppl 1):158–191. https://doi.org/10.1002/hep.31327

Article  PubMed  Google Scholar 

Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S et al (2021) Management of hepatocellular carcinoma in japan: jsh consensus statements and recommendations 2021 update. Liver Cancer 10(3):181–223. https://doi.org/10.1159/000514174

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY et al (2022) Atezolizumab/Bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancers (Basel) 14(7):1747. https://doi.org/10.3390/cancers14071747

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J et al (2023) Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib. Cancer Med 12(1):325–334. https://doi.org/10.1002/cam4.4854

Article  CAS  PubMed  Google Scholar 

Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T et al (2022) Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open 7(6):100591. https://doi.org/10.1016/j.esmoop.2022.100591

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341. https://doi.org/10.1016/j.ijsu.2010.02.007

Article  Google Scholar 

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https://doi.org/10.1186/1745-6215-8-16

Article  PubMed  PubMed Central  Google Scholar 

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z

Article  PubMed  Google Scholar 

Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M et al (2023) Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer 180:9–20. https://doi.org/10.1016/j.ejca.2022.11.017

Article  CAS  PubMed  Google Scholar 

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K et al (2023) Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: multicenter study. Hepatol Res 54(4):382–391. https://doi.org/10.1111/hepr.13991

Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M et al (2022) Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res 52(7):630–640. https://doi.org/10.1111/hepr.13771

Article  CAS  PubMed  Google Scholar 

Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M et al (2022) Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A propensity score matching analysis. Target Oncol 17(6):643–653. https://doi.org/10.1007/s11523-022-00921-x

Article  PubMed  PubMed Central  Google Scholar 

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J et al (2023) Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings. Oncology 101(9):542–552. https://doi.org/10.1159/000530028

Article  CAS  PubMed  Google Scholar 

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M et al (2023) Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer 189:112933. https://doi.org/10.1016/j.ejca.2023.05.021

Article  CAS  PubMed  Google Scholar 

Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M et al (2023) Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol 149(10):7565–7577. https://doi.org/10.1007/s00432-023-04678-2

Article  CAS  PubMed  Google Scholar 

Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC et al (2023) Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med 12(6):7077–7089. https://doi.org/10.1002/cam4.5506

Article